Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -225.67% is 59% below its 5-year average of -142.01%, near the high end of its 5-year range (-684.77%–-42.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.18% below its 12-month average of -225.26%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -225.67%.
RETURN ON EQUITY (ROE)
-225.67%
RETURN ON EQUITY (ROE) AVG TTM
-225.26%
RETURN ON EQUITY (ROE) AVG 3Y
-190.57%
RETURN ON EQUITY (ROE) AVG 5Y
-142.01%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-0.18%
CURRENT VS 3Y AVG
-18.42%
CURRENT VS 5Y AVG
-58.91%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-437.18%
vs the sector median at left
Longeveron Inc.
Market Cap
$7.21M
Return on Equity (ROE)
-225.67%
TTM Avg
-225.26%
3Y Avg
-190.57%
5Y Avg
-142.01%
Market Cap
$7.32M
Return on Equity (ROE)
-1168.44%
TTM Avg
-606.51%
3Y Avg
-330.90%
5Y Avg
-270.23%
Market Cap
$7.29M
Return on Equity (ROE)
N/A
TTM Avg
-159.14%
3Y Avg
523.81%
5Y Avg
82.41%
Market Cap
$7.07M
Return on Equity (ROE)
-120.58%
TTM Avg
-99.12%
3Y Avg
-428.18%
5Y Avg
-321.37%
Market Cap
$6.95M
Return on Equity (ROE)
N/A
TTM Avg
158.93%
3Y Avg
168.21%
5Y Avg
33.14%
Market Cap
$7.08M
Return on Equity (ROE)
-847.90%
TTM Avg
-134.62%
3Y Avg
-211.14%
5Y Avg
-242.56%
Market Cap
$7.02M
Return on Equity (ROE)
-111.46%
TTM Avg
-348.97%
3Y Avg
-374.13%
5Y Avg
-408.25%
Market Cap
$7.01M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$6.97M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Longeveron Inc. (LGVN) | $7.21M | -225.67% | -225.26% | -190.57% | -142.01% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.32M | -1168.44% | -606.51% | -330.90% | -270.23% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.29M | N/A | -159.14% | 523.81% | 82.41% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.07M | -120.58% | -99.12% | -428.18% | -321.37% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.95M | N/A | 158.93% | 168.21% | 33.14% |
| Exicure, Inc. (XCUR)vs › | $7.08M | -847.90% | -134.62% | -211.14% | -242.56% |
| KALA BIO, Inc. (KALA)vs › | $7.02M | -111.46% | -348.97% | -374.13% | -408.25% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.01M | -218.65% | -54.74% | -35.36% | -35.36% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.97M | -370.16% | -148.31% | -87.53% | -43.20% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.78M | -227.37% | -118.13% | -87.25% | -55.09% |
ROE
-225.7%
ROA
-151.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -225.67% |
| 2026-03-31 | -139.95% |
| 2025-12-31 | -400.07% |
| 2025-09-30 | -214.14% |
| 2025-06-30 | -146.48% |
| 2025-03-31 | -98.64% |
| 2024-12-31 | -72.97% |
| 2024-09-30 | -69.92% |
| 2024-06-30 | -124.77% |
| 2024-03-31 | -684.77% |
| 2023-12-31 | -317.65% |
| 2023-09-30 | -299.19% |
| 2023-06-30 | -177.40% |
| 2023-03-31 | -122.39% |
| 2022-12-31 | -91.86% |
| 2022-09-30 | -74.94% |
| 2022-06-30 | -61.46% |
| 2022-03-31 | -50.85% |
| 2021-12-31 | -45.51% |
| 2021-09-30 | -64.17% |
| 2021-06-30 | -42.25% |
| 2021-03-31 | -24.99% |
| 2020-12-31 | -190.24% |
| 2020-09-30 | -85.83% |
